Abstract |
The 15,000-molecular-weight polypeptide (p15) of feline leukemia virus (FeLV) was shown to impair normal lymphocyte function in vitro and to abrogate immunity to feline oncornavirus disease in vivo. FeLVp15 suppressed concanavalin A-induced blast transformation of normal feline lymphocytes by 68%, while other virion proteins had no effect. p15 suppression was not due to toxicity, nor was p15 a competitive inhibitor of concanavalin A binding. Capping of receptors for concanavalin A on normal feline lymphocytes also was inhibited by either inactivated FeLV or FeLV p15. Groups of cats were immunized with either killed feline oncornavirus-associated cell membrane antigen bearing tumor cells or tumor cells plus FeLV p15. After challenge with feline sarcoma virus, three of four p15-treated cats developed progressive fatal fibrosarcoma as compared to one of five non-p15-treated cats. The cats receiving p15 also had lower cytotoxic antibody titers against feline oncornavirus-associated cell membrane antigen (mean peak titer, 1:6) than did the non-p15 group (1:74). These data support the hypothesis that the immunosuppression in cats infected with FeLV is mediated by FeLV p15.
|
Authors | L E Mathes, R G Olsen, L C Hebebrand, E A Hoover, J P Schaller, P W Adams, W S Nichols |
Journal | Cancer research
(Cancer Res)
Vol. 39
Issue 3
Pg. 950-5
(Mar 1979)
ISSN: 0008-5472 [Print] United States |
PMID | 218725
(Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Antigens, Viral
- Viral Proteins
- Concanavalin A
|
Topics |
- Animals
- Antigens, Viral
(administration & dosage)
- Cats
- Concanavalin A
(pharmacology)
- Immunity
- Immunologic Capping
- Immunosuppression Therapy
- In Vitro Techniques
- Leukemia Virus, Feline
(immunology)
- Leukemia, Experimental
(immunology)
- Lymphocyte Activation
- Molecular Weight
- Tumor Virus Infections
(immunology)
- Viral Proteins
(administration & dosage, immunology)
|